FDA Approves Effective Topical Foam for Treating Scalp and Body Plaque Psoriasis
The FDA has approved Zoryve foam, a steroid-free topical treatment for scalp and body plaque psoriasis in adolescents and adults, backed by clinical trial success in clearing psoriasis and relieving itching.
The U.S. Food and Drug Administration (FDA) has granted approval for Zoryve (roflumilast) topical foam 0.3% developed by Arcutis Biotherapeutics, specifically for managing plaque psoriasis affecting the scalp and body. This medication is suitable for adults and adolescents aged 12 years and older. Notably, Zoryve is a steroid-free, once-daily treatment option, offering a convenient approach for patients.
The approval followed positive results from comprehensive clinical trials, including the Phase III ARRECTOR trial and a Phase II trial (Trial 204). In these studies, a total of 736 participants with mild to severe plaque psoriasis on the scalp and body were randomized to apply either Zoryve foam or a placebo foam daily over an eight-week period. The efficacy was assessed using the Investigator Global Assessment (IGA) scale.
Results demonstrated significant improvement, with 66.4% of patients in the ARRECTOR trial achieving success on the Scalp-IGA at week eight, compared to 27.8% treated with placebo. Similarly, 45.5% achieved Body-IGA success versus 20.1% on placebo. The Phase II trial echoed these findings, with 56.7% of patients reaching Scalp-IGA success and 39.0% achieving Body-IGA success.
According to Jennifer Soung, M.D., clinical director at Southern California Dermatology, Zoryve foam not only effectively clears psoriasis plaques but also provides rapid itch relief. Its safety profile supports indefinite use, and its two formulations, cream and foam, offer healthcare providers flexible treatment options.
This approval marks a significant advancement in psoriasis therapy, particularly as it allows for comprehensive management of scalp and body psoriasis with a single prescription, transforming the treatment landscape for patients with this chronic condition.
source: https://medicalxpress.com/news/2025-05-fda-topical-foam-plaque-psoriasis.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative AI Technique Uses Speech Analysis to Detect Early Signs of Neurological Disorders
A novel AI-based speech analysis framework dramatically improves early detection of neurological disorders, offering a noninvasive, accurate, and interpretable diagnostic tool for conditions like Parkinson's and Huntington's disease.
Impact of Early Fluoxetine Exposure on Brain Development in Rats
Research reveals that early exposure to fluoxetine, an antidepressant, can alter brain development and behavior in rats, with potential long-term implications for neurodevelopmental health. Study highlights sex-specific effects and the importance of cautious antidepressant use during pregnancy.
Higher Maternal BMI During Early Pregnancy Increases Risk of Childhood Overweight and Obesity
Higher BMI in women during early pregnancy significantly increases the likelihood of their children developing overweight or obesity by age ten. Supporting women before conception is essential to break the cycle of intergenerational obesity.
Innovative Silicone Models Revolutionize Medical Training and Research in Cerebral Vasculature
Swiss Vascular has developed detailed silicone models of cerebral blood vessels to improve medical training and reduce animal testing, advancing ethical research and clinical procedures.